Company Snapshot
Entrada Therapeutics, Inc. investment report
Start with TRDA at a glance, then work through valuation, price history, fundamentals, management, competitors, and analyst expectations.
Entrada Therapeutics, Inc.
NASDAQ:TRDABiotechnology
+$0.03 today
- Market cap
- $194.19M
- Beta
- -0.26
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.97
Volume 0.43M
Average 0.36M
Intrinsic Value
TRDA Intrinsic Value
Start with the valuation result. Compare the current market price with the system DCF estimate, then use the supporting sections below to decide whether the assumptions are reasonable.
Entrada Therapeutics, Inc.
NASDAQ:TRDA
Intrinsic Alpha fair value
Locked
Current Price
$4.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Monitor TRDA
Get notified when the price moves into your range
Use alerts to turn the valuation into an action plan instead of checking the stock manually.
Price alerts
Get notified when TRDA drops below your target
Current price baseline
$4.96
Current price $4.96
Sign in to activate price alerts.
Price History
How has TRDA traded over time?
Review how the market has priced Entrada Therapeutics, Inc. over time, alongside earnings and dividend events, before deciding whether today’s price is unusual.
Price history
Dividend-adjusted closing price
Period change
-43.76%
Period high
$16.03
Period low
$4.37
Latest
$4.96
Investment Notes
Capture the investment case
Write down the key idea, risks, and what would change your mind before testing the thesis against the fundamentals below.
My notes
Journal entries for TRDA
Sign in to keep notes
Keep your research and decisions in your personal journal.
Fundamental Analysis
Test company quality against your thesis
Work through profitability, revenue mix, financial position, cash generation, compounding numbers, and growth to see whether the business supports the investment case.
Earnings Quality
Follow revenue through to net income
Use the waterfall to see which costs, margins, and operating lines explain how much of each sales dollar becomes profit.
TRDA Earnings Waterfall · TTM
NASDAQ:TRDA · Revenue to Net Income
Key Ratios
Analysis
$5.7M of revenue converted into -$166.1M of net income for the selected period. Gross margin is -534.2% and net margin is -3124.7%, showing how much revenue survives after costs and taxes. EPS is $-4.00, tying the income statement back to per-share earnings.
Revenue Mix
See which products and regions drive the business
Growth is easier to trust when you know where it comes from. Check whether one segment or region carries the company and how the mix is shifting.
Revenue by segment
Where TRDA earns its revenue, as reported in company filings
- License
| Segment · FY2025 | Revenue | Share | YoY |
|---|---|---|---|
| License | $300K | 100.0% | -98.5% |
Figures in USD. Segments account for 1.2% of reported FY2025 revenue; $25.12M is not attributed to a segment.
Financial Position
Check what supports the company underneath the income statement
The balance sheet shows liquidity, debt, asset mix, and book value quality before you rely on earnings or growth assumptions.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $76.4M |
| Short-term Investments | $178.4M |
| Receivables | $2.3M |
| Other Current | $9.7M |
| Total Current Assets | $266.9M |
| PP&E (Net) | $65.3M |
| Other Non-current | $3.4M |
| Total Non-current Assets | $68.6M |
| Total Assets | $335.5M |
Analysis
Selected assets total $335.5M for Latest. The largest visible component is Short-term Investments at $178.4M, about 53.2% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Cash Generation
Test whether profit turns into cash
Free cash flow connects accounting earnings to owner earnings, showing how much cash remains after reinvestment needs.
Free Cash Flow
Net Income to FCF bridge
FY2025
Analysis
FY2025 free cash flow is -$129.6M. FCF conversion is 90.1% of net income. Operating cash flow was -$128.5M, with capex of -$1.0M. The largest bridge item is Stock-Based Comp at $19.6M.
Quality Snapshot
Check the numbers that compound value
Check whether earnings, revenue, equity, cash, and returns on capital are moving in the same direction as your written thesis.
Big Five Numbers
CAGR by period · ROIC shows average
| Metric | 10yr | 5yr | 3yr | 1yr |
|---|---|---|---|---|
EPS | N/A | N/A | N/A | N/A |
Revenue | N/A | N/A | N/A | -87.9% |
Equity | N/A | N/A | +2.9% | -35.6% |
Cash | N/A | N/A | +26.0% | -10.7% |
ROIC | N/A | -18.3% | -11.3% | -43.7% |
Analysis
Latest growth is strongest in Cash at -10.7% and weakest in Revenue at -87.9%. Three-year average ROIC is -11.3%, which helps show whether that growth is being earned efficiently.
Growth Profile
Compare historical growth with forward expectations
Strong past growth matters more when analysts still expect the business to expand without relying on one temporary driver.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +38.0% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +38.0% (5yr), giving you a quick read on expected growth from here.
Management
Judge how Entrada Therapeutics, Inc. allocates capital
Review returns on capital, owner payouts, dividend durability, insider activity, and the leadership responsible for these decisions.
Capital Efficiency
Returns on equity, invested capital, and assets help separate durable operators from businesses that only grow by adding more capital.
Return Metrics
ROE, ROIC & ROA over time
ROE
-47.0%
avg -0.3%
ROIC
-43.7%
avg -32.9%
ROA
-38.1%
avg -24.0%
Analysis
ROA is currently the strongest return metric at -38.1% versus its period average of -24.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Dividend Record
A dividend is more useful when growth, payout ratio, and free cash flow support the current yield.
Dividends
Dividend history, growth & yield
Yield
0.00%
Annual Div/Share
$0.00
Payout Ratio
0.0%
Frequency
—
Shareholder Yield
0.00%
Next Ex-Date
Not announced
Next Payment
—
Analysis
The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.
Owner Returns
Dividends, buybacks, and debt paydown show whether excess cash is being reinvested, returned, or used to strengthen the balance sheet.
Shareholder Returns
Dividend, buyback & debt paydown yields
Dividend Yield (TTM)
0.00%
Buyback Yield (TTM)
0.00%
Debt Paydown (TTM)
0.00%
Total Yield (TTM)
0.00%
Analysis
Total TTM shareholder yield is 0.00% including 0.00% from debt paydown. The largest current contributor is dividends at 0.00%, which helps show whether capital returns are coming from direct cash payouts, share count reduction, or balance sheet cleanup.
Insider Activity
Insider transactions add context to ownership incentives and can reveal when leadership behavior diverges from the public investment case.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$291,162.12
Sells
42
$11.58M
Net Transaction Value
−$11.29M
Net selling
Most Active
MPM BIOVENTURES 2018, L.P.
12 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 9, 26Sep 9, 2026 | MPM BIOVENTURES 2018, L.P. Indirect | Sell | $205.6K$205,607.81 |
| Sep 9, 26Sep 9, 2026 | MPM BioVentures 2014, L.P. Indirect | Sell | $205.6K$205,607.81 |
| Sep 8, 26Sep 8, 2026 | MPM BIOVENTURES 2018, L.P. Indirect | Sell | $1.4M$1,426,425.00 |
| Sep 8, 26Sep 8, 2026 | MPM BioVentures 2014, L.P. Indirect | Sell | $1.4M$1,426,425.00 |
| Sep 4, 26Sep 4, 2026 | MPM BIOVENTURES 2018, L.P. Indirect | Sell | $273.7K$273,735.00 |
| Sep 4, 26Sep 4, 2026 | MPM BioVentures 2014, L.P. Indirect | Sell | $273.7K$273,735.00 |
| Sep 3, 26Sep 3, 2026 | MPM BIOVENTURES 2018, L.P. Indirect | Sell | $231.3K$231,325.71 |
| Sep 3, 26Sep 3, 2026 | MPM BioVentures 2014, L.P. Indirect | Sell | $231.3K$231,325.71 |
| Sep 2, 26Sep 2, 2026 | MPM BIOVENTURES 2018, L.P. Indirect | Sell | $180.7K$180,691.89 |
| Sep 2, 26Sep 2, 2026 | MPM BioVentures 2014, L.P. Indirect | Sell | $180.7K$180,691.89 |
1–10 of 47
Summary
Insiders reported 5 buys worth $291,162.12 and 42 sells worth $11.58M over the last 12 months. That adds up to net selling of $11.29M. MPM BIOVENTURES 2018, L.P. was the most active insider with 12 transactions.
Leadership
Leadership context helps you judge who is responsible for strategy, capital allocation, and execution.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Dipal Doshi | Chief Executive Officer & Director | USDÂ 998.25K | 50 | 517.29K | 1.33% |
Natarajan Sethuraman | President of Research & Development | USDÂ 768K | 64 | 214.24K | 0.55% |
Nathan J. Dowden | President & Chief Operating Officer | USDÂ 737.18K | 55 | 196.06K | 0.51% |
Kerry Robert | Senior Vice President of People | — | — | — | — |
Jared Cohen | General Counsel | — | — | — | — |
Kevin Healy | Senior Vice President of Regulatory Affairs | — | — | — | — |
Kory James Wentworth | Chief Financial Officer & Treasurer | — | 47 | 117.28K | 0.30% |
Karla MacDonald | Chief Corporate Affairs Officer | — | — | — | — |
Linea Aspesi | Chief People Officer | — | 56 | — | — |
Sandeep Basnet | Head of Information Technology | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 2, 2026.
Alternatives to TRDA
Compare Entrada Therapeutics, Inc. with similar companies
A stock can look attractive in isolation and still be less compelling than a peer. Check competitors before committing to the thesis.
Competitors
Peer companies in the same sector
Analysts
What Wall Street expects from TRDA
Compare consensus price targets and ratings with your own valuation to understand how much optimism the market is already pricing in.
Analyst Targets
See where analysts expect TRDA to trade next
Compare the latest consensus target range with the current share price to understand how much upside or downside Wall Street is pricing in.
Wall Street price targets
1-year price history with analyst consensus target
Unlock analyst target range
Sign in free to see low, average, high targets and implied upside for TRDA.
Analyst Ratings
How analysts rate TRDA today
See the buy, hold, and sell split behind the consensus and whether recent rating changes lean toward upgrades or downgrades.
Analyst ratings
Buy, hold, and sell recommendations and recent rating changes
Unlock analyst ratings
Sign in free to see the buy/hold/sell breakdown and recent rating changes for TRDA.
Company Overview
Understand how Entrada Therapeutics, Inc. makes money
Ground the financial evidence in the company profile, business description, and key facts.
Key Information
Stock Analysis
Turn the TRDA report into your next decision
Record your conclusion, evidence, and concerns in a structured analysis workspace.
Investment analysis
Turn TRDA research into a decision
Work through Know the Business, Test the Moat, Management, and Intrinsic Value in one private, repeatable checklist.
Sign in on the next page to save a private analysis.
Start analysisFAQ
Common questions about TRDA
Resolve the remaining questions before moving into the detailed workspaces.
Explore
Continue your research
Open the detailed valuation, financial, health, and management workspaces.
Continue the stock analysis
Jump to another research area for this company.